Search

Immunotherapy / Systemic Therapy

A074

IMMUNE DYNAMICS IN RESPONSE TO PD-1 BLOCKADE IN MURINE ORAL CAVITY CANCER

Immunotherapy / Systemic Therapy

Katherine C Wai, MD; Lauren S Levine, MD; Iliana Tenvooren, MS; Patrick K Ha, MD; Mekhail Anwar, MD, PhD; Matthew H Spitzer, PhD

University of California San Francisco


A075

BLOOD EOSINOPHIL COUNT MAY PREDICT SEVERE IMMUNE-RELATED ADVERSE EVENTS DUE TO NIVOLUMAB IN RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunotherapy / Systemic Therapy

Yushi Ueki, MD, PhD; Takeshi Takahashi, MD; Ryusuke Shodo, MD, PhD; Keisuke Yamazaki, MD, PhD; Arata Horii, MD, PhD

Department of Otolaryngology Head and Neck Surgery Niigata University Faculty of Medicine


A077

REAL WORLD OUTCOMES IN PATIENTS WITH HNSCC TREATED WITH CHECKPOINT INHIBITION

Immunotherapy / Systemic Therapy

Sara B Hobday1; Robert M Brody, MD1; Barry A Kriegsman, MD, PhD1; Devraj Basu, MD, PhD, FACS2; Jason Newman, MD, FACS1; Roger B Cohen, MD3; Abigail Doucette4; Lova Sun, MD, MSCE5

1Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, The Wistar Institute, Philadelphia, PA; 3Abramson Cancer Center of the University of Pennsylvania, Philadelphia PA; 4Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA; 5Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA


A078

RACIAL REPRESENTATION IN CLINICAL TRIALS OF IMMUNE CHECKPOINT INHIBITORS IN HEAD AND NECK CANCER

Immunotherapy / Systemic Therapy

Grace M Amadio, BS1; Anita Sulibhavi, MD2; Olivia Given Costello, MLIS3; Jeffrey C Liu, MD2

1Lewis Katz School of Medicine at Temple University; 2Department of Otolaryngology, Head and Neck Surgery, Temple University, Philadelphia, PA; 3Charles Library, Temple University


A079

COMPUTATIONAL AND IN VITRO EVALUATION OF SHARED IMMUNOGENIC NEOANTIGENS IN ADENOID CYSTIC CARCINOMA

Immunotherapy / Systemic Therapy

James A Cevallos, MS1; Catherine Y Han, BS2; Fengshen Kuo, PhD3; Jingming Wang, PhD3; Zaineb Nadeem, MS3; Patrick Ha, MD1; Luc Morris, MD, MSc3

1UCSF; 2Weill Cornell Medicine; 3Memorial Sloan Kettering Cancer Center


A080

ONCOLOGIC QUALITY METRICS IN PATIENTS WITH OPERABLE MUCOSAL HEAD AND NECK SQUAMOUS CELL CARCINOMA ENROLLED IN NEOADJUVANT TARGETED THERAPY TRIALS

Immunotherapy / Systemic Therapy

Marco A Mascarella, MD; Varun Vendra; Mark W Kubik; Shaum Sridharan; Seungwon Kim; Robert L Ferris; Moon J Fenton; James P Ohr; Dan P Zandberg; Umamaheswar Duvvuri

University of Pittsburgh Medical Center


AHNS05

NEUTROPHIL TO LYMPHOCYTE RATIO AND PERIPHERAL BLOOD BIOMARKERS CORRELATE WITH OUTCOMES AMONG PATIENTS WITH RECURRENT METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA AND SALIVARY GLAND CANCER TREATED ON A PHASE II TRIAL OF PEMBROLIZUMAB AND VORINOSTAT

Immunotherapy / Systemic Therapy

Cassie Pan1; Qian (Vicky) Wu2; Jenna Voutsinas2; Jeffrey J Houlton1; Brittany Barber1; Neal Futran1; Renato G Martins3; Jonathan R Fromm4; Cristina P Rodriguez3

1Department of Otolaryngology, University of Washington, Seattle, WA; 2Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 3Division of Oncology, Department of Medicine, University of Washington, Seattle, WA; 4Department of Laboratory Medicine, University of Washington, Seattle, WA


AHNS09

EFFECT OF PREOPERATIVE IMMUNOTHERAPY ON COMPLICATIONS AFTER HEAD AND NECK SURGERY

Immunotherapy / Systemic Therapy

Ramez Philips, MD; Angela Alnemri; Adam Luginbuhl, MD; David Cognetti, MD; Joseph Curry, MD

Thomas Jefferson University Hospitals